NCT06567717View on ClinicalTrials.gov

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Zinc

Zinc has not previously been investigated in the treatment of IPF.

OTHER

Placebos for zinc and nicotinamide riboside

These will be identical in appearance to the active substances

DRUG

Nicotinamide riboside

Nicotinamide riboside has not previously been investigated in the treatment of IPF.

Trial Locations (1)

90048

Cedars-Sinai, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER